Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
General17 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News21 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
Noosa News21 hours agoWest End icon closes doors
-
General23 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay